Design and Optimization of Sustain Release Drug Delivery System of Loxoprofen

The goal of the present study was to develop and optimize loxoprofen-loaded microspheres for sustained-release drug delivery system. Loxoprofen is a potent NSAID prodrug belonging to the BSC class II drug with high permeability and low solubility. It is utilized to treat long-term pain and inflammatory disorders.

Microspheres were developed using the protein gelation technique, with varying concentrations of egg albumin and Tween 80 as suggested by the Box-Behnken design. The spherical morphology of the microspheres was confirmed through Scanning electron microscopy. The formulation with the most desirable size of particle and entrapment efficacy was chosen.

The microspheres exhibited a particle size (PS) of 191.27nm and entrapment efficacy (EE) of 78.98%, with a low deviation. Batch F9 showed the optimal results. In vitro investigations showed that pure LOX was released completely within 1 hour, while LOX-loaded microspheres released 88.07% within 8 hours. The formulation exhibited short-term stability, maintaining its integrity and properties when stored at room temperature.

Loxoprofen-loaded egg albumin microspheres can be a potential sustained-release drug delivery, offering a controlled and prolonged release of therapeutically active drug concentrations at the target site.